Searched for
CIPLA DIABETES DRUG
These large- mid- and small-cap stocks can give more than 25% return in 1 year, according to analystsAs the bulls attempt another serious comeback, the market again faces a familiar question: Are valuations still too high, or have they reac...- Cipla appoints health chief Shivam Puri to lead One India businessCipla has appointed Shivam Puri as the new Chief Executive Officer for its One India Business. This significant leadership change will take...
- Cipla is aiming for 40-50 global product filings in three years, says MD Achin GuptaCipla is charting its next growth phase with a strong focus on innovation, complex generics, and biosimilars. The company plans significant...
- Innovation, biosimilars, complex generics to drive Cipla's growth: Achin Gupta, MD & Group CEOAs Cipla approaches its centenary, the company is redefining its strategy by prioritizing innovation to amplify revenues. With ambitions to...
- Pharma stocks buck market weakness as Dr Reddy's gainsPharma stocks showed strength on Thursday, defying market weakness. Dr Reddy's Laboratories saw significant gains, fueled by anticipation o...
- Alkem Labs CEO Vikas Gupta may exit companyAlkem Labs, a leading Indian drug maker, is set for a top management change. Vikas Gupta, the CEO for nearly three years, is expected to de...
- Mounjaro sales dip amid price war as semaglutide generics gain groundMounjaro, the star pharmaceutical from Eli Lilly, is experiencing a downturn in sales across India. This slump can be attributed to competi...
- Glenmark set to join peers in 'Semaglutide' pushGlenmark Pharmaceuticals is set to launch affordable versions of the popular anti-diabetes and obesity drug semaglutide. This move escalate...
- Cipla launches inhalable insulin for diabetes careCipla has launched a new orally inhaled insulin powder for diabetes patients in India. This needle-free alternative to injections offers a ...
- Cipla launches drug for obesity, diabetesCipla has launched Yurpeak, a new injectable medication for obesity and type-2 diabetes. This one-weekly therapy, tirzepatide, is now avail...
- Cipla shares in focus after receiving CDSCO nod to launch inhalation insulinCipla has secured exclusive rights to distribute and market Afrezza, an inhalable insulin, in India. Developed by MannKind, Afrezza offers ...
- Cipla gets CDSCO nod to launch inhalation insulinCipla received approval from CDSCO to distribute and market Afrezza, an inhalable insulin, in India. Developed by MannKind, Afrezza offers ...
- India pharma companies develop versions of Wegovy to get in on weight-loss windfallIndian drugmakers are developing their versions of Novo Nordisk's weight-loss treatment, Wegovy, aiming to capitalize on the growing weight...
- Cipla vows to crack diabetes segment with licensed branded portfolio"Cipla historically has always been a big respiratory and acute player but not that big in the diabetes area," said Umang Vohra, managing d...
- Cipla launches diagnostic device for multiple health conditionsThe company said with the device the company has expanded its product offerings for diagnostics laboratories and aims to bridge the current...
- Cipla to sell Lilly's Trulicity, Humalog diabetes treatments in IndiaThis will allow Cipla to expand access to the drugs in the country with the second-highest number of diabetic people in the world. India ha...
- Cipla shares rise after Vysov anti-diabetic drug acquisitionCipla has been co-marketing Vildagliptin in agreement with Novartis under brand names Vysov and Vysov M (Vildagliptin plus Metformin), the ...
- Cipla to market Novartis, and J&J’s products, while Alkem partners Dong A of South KoreaAlkem is bringing in a fresh brand. Evogliptin has been approved in South Korea and the company is waiting for an approval from the USFDA a...
- Merck unit sues Glenmark Pharmaceuticals for infringing patent on diabetes drugsA unit of US drugmaker Merck & Co sued India's Glenmark Pharmaceuticals on Tuesday for infringing its patent on two diabetes drugs.
- India's diabetes drugs market grew 22% at $700 million in FY12The domestic diabetes drugs market for FY 12 grew 22 per cent at $ 700 million, according to a Credit Suisse report.
Load More
